Clinical Trial

Evaluating the Safety and Efficacy of Duloxetine in the Prevention of Post Endoscopic Retrograde Cholangiopancreatography Pancreatitis

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated November 18, 2025 (before its estimated June 20, 2026 completion). Its status may not reflect the trial's current state.
Summary
Endoscopic retrograde cholangiopancreatography (ERCP (, a key tool that is used in diagnosis and treatment of pancreato-biliary diseases. Post-ERCP pancreatitis (PEP) is the most common and serious complication that can occur following this procedure and can lead to significant morbidity and mortality. A variety of patient-related and procedure-related factors have been associated with higher rates of PEP.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-03-01; most recent amendment 2025-11-17.
Status change: Not Yet Recruiting → Recruiting 2025-03-16
Trial Details
NCT Number NCT06860984
Lead Sponsor Tanta University
Conditions Biliary Disease
Enrollment 44 participants
Start Date 2025-03-10
Primary Completion 2026-06-20 (estimated)
Study Completion 2026-07-10 (estimated)
Updated on ClinicalTrials.gov 2025-11-18